Dr Martens has maintained its full year guidance as it makes ‘good progress’ on turnaround in the US

For the 13 weeks to December 29, 2024, Dr Martens reported a 3% rise in group revenue on a constant currency basis to hit £267m.

Group whoelsale revenue was also up 9% during the period, while direct-to-consumer revenue edged up by 1%.

With an eye to the Americas, direct-to-consumer bounced back with revenue up 4%, in the Asia Pacific direct-to-consumer revenue increase by 17% but in Europe, the Middle East and Africa it fell 5%.

Dr Martens added that its wholesale revenue performance by region was “in line with expectations”.

The fashion business hailed the success of its return to DTC growth in the Americas and credited its success in the Asia Pacific region to “good growth” in Japan.

Dr Martens said its guidance and outlook for the 2025 full financial year remains “unchanged” and it is “on track” to achieve its objectives.

Dr Martens chief executive Ije Nwokorie, who stepped into the role of chief executive earlier this month, said:  “I am excited to be CEO of Dr. Martens. The global relevance of our iconic brand, the strength of our product line and the passionate commitment of our team give me great confidence for FY25 and beyond.

“Our Q3 trading was as expected and our outlook for FY25 remains unchanged. We have made good progress against our objective of turning around our USA performance, with USA DTC in positive growth in Q3. We continue to actively manage our costs and are on track to meet our inventory reduction target for FY25. The team and I are squarely focused on returning the business to sustainable and profitable growth.”